Safety of regadenoson positon emission tomography stress testing in orthotopic heart transplant patients

  • John J. LazarusEmail author
  • Ashraf Saleh
  • Michael Ghannam
  • Keith Aaronson
  • Monica Colvin
  • Frank Pagani
  • Todd Koelling
  • James R. Corbett
  • Richard L. Weinberg
  • Venkatesh L. Murthy
  • Matthew C. Konerman
Original Article



We sought to determine the safety of regadenoson (REG) stress testing in patients who have undergone orthotopic heart transplantation (OHT).


Routine screening for cardiac allograft vasculopathy (CAV) is necessary after OHT. Adenosine stress is contraindicated after heart transplantation due to supersensitivity in denervated hearts. Safety of regadenoson stress following OHT has not been well studied.


We retrospectively reviewed data from OHT patients (N = 123) who were referred to REG stress testing. Medical records were reviewed to determine hemodynamic and ECG response to regadenoson and to identify adverse reactions.


No serious adverse events occurred. No life-threatening arrhythmias or hemodynamic changes occurred. Common side-effects related to regadenoson were observed, dyspnea being the most frequent (66.7%). On average the heart rate rose from 82.8 ± 12 to 95.7 ± 13.4 bpm (P < 0.001), systolic blood pressure decreased from 138.7 ± 20.9 to 115.9 ± 23.9 mmHg (P < 0.001) and mean arterial pressure decreased from 103.5 ± 14.1 to 84.72 ± 15.90 mmHg (P < 0.001) during stress protocol. There was no sustained ventricular tachycardia, ventricular fibrillation, or second-or third-degree atrioventricular block.


Regadenoson stress testing appears to be well tolerated and safe in OHT patients.


Positon emission tomography pharmacologic stress cardiac transplantation regadenoson safety heart failure 



Cardiac allograft vasculopathy


Orthotropic heart transplant


Coronary intravascular ultrasound




Positron emission tomography and myocardial perfusion imaging using regadenoson


Ventricular tachycardia


Ventricular fibrillation



Dr. Murthy is supported by 1R01HL136685 from the National, Heart, Lung, and Blood Institute. Dr. Murthy has received consulting/speaking fees from Bracco Diagnostics and Ionetix. Dr. Murthy owns stock in General Electric.


Keith Aaronson has received consultant or speaking fees from Medtronic, NuPulseCV and has stock options with ProCyrion and NuPulseCV. He has received grants or grants pending from Amgen, Medtronic and Thoratec. Venkatesh L. Murthy has received consulting/speaking fees from Bracco Diagnostics and Ionetix. He owns stock in General Electric. John J. Lazarus, Ashraf Saleh, Michael Ghannam, Monica Colvin, Frank Pagani, Todd Koelling, James R. Corbett, Richard L. Weinberg, and Matthew C. Konerman have no reported conflicts of interest.

Supplementary material

12350_2018_1466_MOESM1_ESM.pptx (149 kb)
Supplementary material 1 (PPTX 148 kb)


  1. 1.
    Lund LH, Edwards LB, Kucheryavaya AY, Benden C, Christie JD, Dipchand AI, Dobbels F, Goldfarb SB, Levvey BJ, Meiser B, Yusen RD, Stehlik J, International Society of H and Lung T. The registry of the International Society for Heart and Lung Transplantation: thirty-first official adult heart transplant report - 2014; focus theme: retransplantation. J Heart Lung Transplant 2014;33:996-1008.CrossRefPubMedGoogle Scholar
  2. 2.
    Wilhelm MJ. Long-term outcome following heart transplantation: current perspective. J Thorac Dis 2015;7:549-51.PubMedPubMedCentralGoogle Scholar
  3. 3.
    Costanzo MR, Dipchand A, Starling R, Anderson A, Chan M, Desai S, Fedson S, Fisher P, Gonzales-Stawinski G, Martinelli L, McGiffin D, Smith J, Taylor D, Meiser B, Webber S, Baran D, Carboni M, Dengler T, Feldman D, Frigerio M, Kfoury A, Kim D, Kobashigawa J, Shullo M, Stehlik J, Teuteberg J, Uber P, Zuckermann A, Hunt S, Burch M, Bhat G, Canter C, Chinnock R, Crespo-Leiro M, Delgado R, Dobbels F, Grady K, Kao W, Lamour J, Parry G, Patel J, Pini D, Towbin J, Wolfel G, Delgado D, Eisen H, Goldberg L, Hosenpud J, Johnson M, Keogh A, Lewis C, O’Connell J, Rogers J, Ross H, Russell S, Vanhaecke J, International Society of H and Lung Transplantation G. The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. J Heart Lung Transplant 2010;29:914-56.CrossRefPubMedGoogle Scholar
  4. 4.
    Bangalore S, Bhatt DL. Coronary intravascular ultrasound. Circulation 2013;127:e868-74.CrossRefPubMedGoogle Scholar
  5. 5.
    St Goar FG, Pinto FJ, Alderman EL, Valantine HA, Schroeder JS, Gao SZ, Stinson EB, Popp RL. Intracoronary ultrasound in cardiac transplant recipients. In vivo evidence of “angiographically silent” intimal thickening. Circulation 1992;85:979-87.CrossRefPubMedGoogle Scholar
  6. 6.
    Al-Mallah MH, Arida M, Garcia-Sayan E, Assal C, Zegarra GT, Czerska B, Ananthasubramaniam K. Safety of adenosine pharmacologic stress myocardial perfusion imaging in orthotopic cardiac transplant recipients: a single center experience of 102 transplant patients. Int J Cardiovasc Imaging 2011;27:1105-11.CrossRefPubMedGoogle Scholar
  7. 7.
    Ellenbogen KA, Thames MD, DiMarco JP, Sheehan H, Lerman BB. Electrophysiological effects of adenosine in the transplanted human heart. Evidence of supersensitivity. Circulation 1990;81:821-8.CrossRefPubMedGoogle Scholar
  8. 8.
    Lieu HD, Shryock JC, von Mering GO, Gordi T, Blackburn B, Olmsted AW, Belardinelli L, Kerensky RA. Regadenoson, a selective A2A adenosine receptor agonist, causes dose-dependent increases in coronary blood flow velocity in humans. J Nucl Cardiol 2007;14:514-20.CrossRefPubMedGoogle Scholar
  9. 9.
    Cavalcante JL, Barboza J, Ananthasubramaniam K. Regadenoson is a safe and well-tolerated pharmacological stress agent for myocardial perfusion imaging in post-heart transplant patients. J Nucl Cardiol 2011;18:628-33.CrossRefPubMedGoogle Scholar
  10. 10.
    Cerqueira MD, Nguyen P, Staehr P, Underwood SR, Iskandrian AE, Investigators A-MT. Effects of age, gender, obesity, and diabetes on the efficacy and safety of the selective A2A agonist regadenoson versus adenosine in myocardial perfusion imaging integrated ADVANCE-MPI trial results. JACC Cardiovasc Imaging 2008;1:307-16.CrossRefPubMedGoogle Scholar
  11. 11.
    Iskandrian AE, Bateman TM, Belardinelli L, Blackburn B, Cerqueira MD, Hendel RC, Lieu H, Mahmarian JJ, Olmsted A, Underwood SR, Vitola J, Wang W, Investigators AM. Adenosine versus regadenoson comparative evaluation in myocardial perfusion imaging: results of the ADVANCE phase 3 multicenter international trial. J Nucl Cardiol 2007;14:645-58.CrossRefPubMedGoogle Scholar
  12. 12.
    Gordi T, Frohna P, Sun HL, Wolff A, Belardinelli L, Lieu H. A population pharmacokinetic/pharmacodynamic analysis of regadenoson, an adenosine A2A-receptor agonist, in healthy male volunteers. Clin Pharmacokinet 2006;45:1201-12.CrossRefPubMedGoogle Scholar
  13. 13.
    Mc Ardle BA, Davies RA, Chen L, Small GR, Ruddy TD, Dwivedi G, Yam Y, Haddad H, Mielniczuk LM, Stadnick E, Hessian R, Guo A, Beanlands RS, deKemp RA, Chow BJ. Prognostic value of rubidium-82 positron emission tomography in patients after heart transplant. Circ Cardiovasc Imaging 2014;7:930-7.CrossRefPubMedGoogle Scholar
  14. 14.
    Wu YW, Chen YH, Wang SS, Jui HY, Yen RF, Tzen KY, Chen MF, Lee CM. PET assessment of myocardial perfusion reserve inversely correlates with intravascular ultrasound findings in angiographically normal cardiac transplant recipients. J Nucl Med 2010;51:906-12.CrossRefPubMedGoogle Scholar
  15. 15.
    Murthy VL, Naya M, Foster CR, Hainer J, Gaber M, Di Carli G, Blankstein R, Dorbala S, Sitek A, Pencina MJ, Di Carli MF. Improved cardiac risk assessment with noninvasive measures of coronary flow reserve. Circulation 2011;124:2215-24.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© American Society of Nuclear Cardiology 2018

Authors and Affiliations

  • John J. Lazarus
    • 1
    Email author
  • Ashraf Saleh
    • 1
  • Michael Ghannam
    • 1
  • Keith Aaronson
    • 1
  • Monica Colvin
    • 1
  • Frank Pagani
    • 1
  • Todd Koelling
    • 1
  • James R. Corbett
    • 1
  • Richard L. Weinberg
    • 1
  • Venkatesh L. Murthy
    • 1
  • Matthew C. Konerman
    • 1
  1. 1.University of Michigan Frankel Cardiovascular CenterAnn ArborUSA

Personalised recommendations